Description: Advanced Solid Tumors: ABBV-400 as Monotherapy-A Global First-in-Human Study Target Patient Population: All solid tumors Study Design: Study drug is administered IV every 3 weeks For more information on this trial, read its profile on clinicaltrials.gov here.
Archives: Clinical Trials
C-1400-01 (AGEN1777) (Agenus, Inc.)
C-1400-01 (AGEN1777) (Agenus, Inc.) Description: A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination with PD-1 Inhibition in Patients With Advanced Solid Tumors Target Population: All solid tumors. To be given as single agent or in combination with Balstilimab Study Design: Study drug is administered IV every 3 weeks.
AT148002 (ALX Oncology)
AT148002 (ALX Oncology) Description: A Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS) Mechanism of Action: ALX148 is a CD47 blocker. Target Patient Population: High Risk MDS Study Design: Study Drug will be administered IV every 2 or 4 weeks. Combination drug, Azacitidine given as would
ALPN-202-NEON-1 (Alpine Immune Sciences)
ALPN-202 – NEON-1 (Alpine Immune Sciences) Description: An open-Label Study of ALPN-202 In Subjects With Advanced Malignancies (NEON-1) Target Patient Population: Currently in expansion for Melanoma, Renal cell and PDL1 positive cancers only Study Design: Study drug is administered IV every 1 or 3 weeks
ALPN-202-NEON-2 (Alpine Immune Sciences)
A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency (CAPItello-281) Principal Investigator: Dr. Eric Batts For more information on this trial, read its profile on clinicaltrials.gov here.
A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumours PI: Dr. Chandana Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion For more information on this
AstraZeneca D8227C00001 (ACERTA ESCALADE)
Description: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma Principal Investigator: Dr. Brett Brinker For more information on this trial, read its profile on clinicaltrials.gov here.
A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC-9) PI: Dr. Chen Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer